Predictive and Presymptomatic Testing Market Report 2026

The predictive and presymptomatic testing market size has grown rapidly in recent years. It will grow from $5.78 billion in 2025 to $6.37 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to advancements in genetic sequencing technologies, increasing awareness of inherited disease risks, expansion of clinical genetic testing services, growth of oncology and neurology testing programs, declining costs of genetic testing.

The predictive and presymptomatic testing market size is expected to see strong growth in the next few years. It will grow to $9.31 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising integration of AI in genomic analysis, expansion of population-scale screening programs, growing focus on preventive healthcare strategies, increasing regulatory support for genetic diagnostics. Major trends in the forecast period include growing adoption of preventive genetic screening, rising use of risk-based disease prediction models, expansion of genetic counseling services, increased focus on early disease detection, integration of genomic data in clinical decision-making.

The increasing prevalence of genetic disorders is expected to drive the growth of the predictive and presymptomatic testing market in the coming years. Genetic disorders are illnesses caused by abnormalities in deoxyribonucleic acid (DNA), including gene mutations and chromosomal alterations, with examples such as cystic fibrosis and Down syndrome. The rising occurrence of genetic disorders is linked to factors like advanced maternal age, environmental influences, and improved diagnostic techniques. Predictive and presymptomatic testing plays a vital role in lowering the impact of genetic disorders by identifying individuals at risk before symptoms appear. This proactive strategy enables early interventions or lifestyle changes that can help prevent or lessen the severity of these conditions. For example, in June 2023, the American Society of Gene and Cell Therapy, a U.S.-based non-profit medical and scientific organization, reported that the number of gene therapies in Phase III clinical trials increased by 10% in the third quarter of 2023, marking the first quarterly rise since the third quarter of 2022. Consequently, the growing prevalence of genetic disorders is fueling the predictive and presymptomatic testing market.

Major companies in the predictive and presymptomatic testing market are concentrating on creating innovative multi-gene testing solutions with improved genetic risk-scoring capabilities to allow earlier disease prediction and enhance personalized prevention strategies. Polygenic-enabled panels integrate sequencing of clinically significant hereditary-risk genes with the analysis of multiple common variants, offering a more comprehensive and individualized evaluation of future disease risk compared to traditional single-gene tests. For example, in November 2025, Myriad Genetics Inc., a U.S.-based molecular diagnostics company, expanded its MyRisk Hereditary Cancer Test to cover 63 clinically actionable genes across more than 11 cancer types. The expanded panel combines next-generation sequencing with personalized lifetime and five-year cancer-risk estimates, helping physicians guide proactive clinical decision-making. This product improves risk detection even in individuals without a strong family history and supports targeted surveillance, earlier screening, and preventive care planning.

In July 2023, New Day Diagnostics, a U.S.-based diagnostics and CRO services company, acquired substantially all assets of Epigenomics AG for up to US$12.05 million. Through this acquisition, New Day Diagnostics intends to strengthen its early colorectal cancer screening capabilities by incorporating Epigenomics’ blood-based Epi proColon test and related biomarker technologies. Epigenomics AG, a Germany-based molecular diagnostics company, offers non-invasive colorectal cancer screening through its Epi proColon blood test.

Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.

North America was the largest region in the predictive and presymptomatic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the predictive and presymptomatic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the predictive and presymptomatic testing market by increasing costs of imported sequencing instruments, reagents, bioinformatics software, and laboratory automation systems. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs for advanced testing platforms. These tariffs can raise testing prices and limit accessibility. However, they are also driving domestic production of reagents, local development of bioinformatics tools, and regional expansion of genetic testing infrastructure.

The predictive and presymptomatic testing market research report is one of a series of new reports that provides predictive and presymptomatic testing market statistics, including predictive and presymptomatic testing industry global market size, regional shares, competitors with a predictive and presymptomatic testing market share, detailed predictive and presymptomatic testing market segments, market trends and opportunities, and any further data you may need to thrive in the predictive and presymptomatic testing industry. This predictive and presymptomatic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Predictive and presymptomatic testing are types of genetic tests aimed at evaluating an individual's likelihood of developing a disease before any symptoms appear, particularly for inherited disorders. These tests assist in identifying individuals at higher risk for specific genetic conditions, allowing for early intervention and personalized healthcare. The advantages include timely diagnosis, customized prevention strategies, and informed lifestyle decisions.

The primary categories of predictive and presymptomatic testing are predictive testing and presymptomatic testing. Predictive testing assesses whether an individual has a genetic tendency to develop a particular condition or disease in the future, even if they are currently symptom-free. Its applications include genetic testing for cancer, cardiovascular disorders, neurological conditions, and others, and it is utilized by a range of end users, including hospitals and clinics, diagnostic laboratories, research institutes, and more.

The predictive and presymptomatic testing market consists of revenues earned by entities by providing services such as genetic testing, risk assessment, early disease detection, biomarker testing, and predictive modelling. The market value includes the value of related goods sold by the service provider or included within the service offering. The predictive and presymptomatic testing market also includes sales of carrier screening tests, genetic tests, diagnostic tools, prenatal testing kits, and Alzheimer's disease biomarkers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.